Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06834035
PHASE1/PHASE2
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
Sponsor: M. Peter Marinkovich
View on ClinicalTrials.gov
Summary
The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.
Key Details
Gender
All
Age Range
6 Years - Any
Study Type
INTERVENTIONAL
Enrollment
8
Start Date
2025-08-04
Completion Date
2027-03
Last Updated
2026-03-25
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
Immunoglobulin G
Purified IgG from human serum, delivered via IV
Locations (1)
Stanford University
Redwood City, California, United States